Compare LBTYA & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBTYA | ABCL |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | Bermuda | Canada |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.5B |
| IPO Year | 2013 | 2020 |
| Metric | LBTYA | ABCL |
|---|---|---|
| Price | $10.49 | $11.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $13.72 | $8.40 |
| AVG Volume (30 Days) | 1.9M | ★ 5.2M |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $11,541,500,000.00 | $75,128,000.00 |
| Revenue This Year | $15.41 | N/A |
| Revenue Next Year | $3.03 | $21.85 |
| P/E Ratio | $10.93 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $9.43 | $2.75 |
| 52 Week High | $13.52 | $12.58 |
| Indicator | LBTYA | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 56.96 |
| Support Level | $10.45 | $10.44 |
| Resistance Level | $10.98 | $12.58 |
| Average True Range (ATR) | 0.26 | 0.65 |
| MACD | -0.01 | -0.27 |
| Stochastic Oscillator | 52.08 | 37.61 |
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.